Weitzberg E, Hemsén A, Lundberg J M, Ahlborg G
Department of Anesthesiology and Intensive Care, Karolinska Hospital, Stockholm, Sweden.
J Appl Physiol (1985). 1995 Oct;79(4):1255-9. doi: 10.1152/jappl.1995.79.4.1255.
To investigate splanchnic and renal vascular effects and elimination of endothelin-3 (ET-3), ET-3 (10 pmol.kg-1.min-1 iv for 20 min) was given to six healthy male volunteers. Arterial plasma ET-3-like immunoreactivity (ET-3-Li) increased 10-fold to 111 +/- 31 pmol/l (P < 0.01). The initial half-life of plasma ET-3-Li determined in three subjects was 1.7 +/- 0.2 min. The fractional extraction of ET-3-Li was 68 +/- 7% in the splanchnic and 63 +/- 4% in the renal vascular beds. Mean arterial blood pressure fell from 86 +/- 4 to 94 +/- 4 mmHg (10%) (P < 0.05). Splanchnic and renal blood flows fell by 43 +/- 3% (P < 0.05) and 29 +/- 4% (P < 0.05), respectively, during the infusion. Splanchnic and renal vascular resistances rose by 92 +/- 22% (P < 0.05) and 58 +/- 7% (P < 0.05). In conclusion, ET-3 infusion in humans induces splanchnic and renal vasoconstriction of similar magnitude as previously shown during endothelin-1 infusion, presumably by ETB receptor activation. Plasma ET-3 is efficiently extracted in the splanchnic and renal vascular regions.
为研究内脏和肾血管效应以及内皮素 -3（ET -3）的清除情况，对6名健康男性志愿者静脉输注ET -3（10 pmol·kg⁻¹·min⁻¹，持续20分钟）。动脉血浆中ET -3样免疫反应性物质（ET -3-Li）增加了10倍，达到111±31 pmol/L（P<0.01）。在3名受试者中测定的血浆ET -3-Li的初始半衰期为1.7±0.2分钟。ET -3-Li在内脏血管床的分数提取率为68±7%，在肾血管床为63±4%。平均动脉血压从86±4 mmHg降至94±4 mmHg（下降10%）（P<0.05）。在输注过程中，内脏血流量和肾血流量分别下降了43±3%（P<0.05）和29±4%（P<0.05）。内脏血管阻力和肾血管阻力分别升高了92±22%（P<0.05）和58±7%（P<0.05）。总之，在人体中输注ET -3会引起与先前输注内皮素 -1时相似程度的内脏和肾血管收缩，推测是通过ETB受体激活所致。血浆ET -3在内脏和肾血管区域被有效提取。
